Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS to send a second group of first-year students overseas
2011-03-23

Some of the students who were chosen in 2010

Following the resounding success of the University of the Free State’s (UFS) Student Leadership Development Programme in 2010, the UFS will send a second group of students to the USA in 2011 and also extend the programme by sending students to various universities in Europe and Asia.

This year a total of 150 first-year students will be selected compared to the 71 students that were selected last year. Last year’s group of students spent two weeks, between September and October 2010, at various universities across the United States.
                                         
The programme intends to expose the students to diverse cultures and enable them to learn leadership skills. The goal of the programme is to build a new class of UFS students who become leaders during their years of study and commit to building a non-racial community during and beyond their years at university.
 
Mr Rudi Buys, the UFS Dean of Student Affairs, says: “With the programme we want to develop participants’ thinking and capacity to lead in the contexts of diversity and change and we hope to direct them to programmes leading to change in student life in general upon their return.”
 
The three core purposes of allowing students an opportunity to study abroad are:
  • to introduce South African students to positive models of racial integration and integrated residential life;
  • to share and exchange ideas around issues of race, racism, racial integration and racial reconciliation, with undergraduate students abroad; and
  • to build long-term networking and collaboration between academics and researchers interested in scholarly work on themes of race, reconciliation and social justice.
 
Last year students were selected based on their ability to reflect critically on knowledge of societal issues and successful candidates were put through a preparatory development programme. They were divided into groups and given assignments to complete during the programme. A similar selection process will be undertaken this year.
 
Upon their return, last year’s group of students demonstrated extremely positive outcomes, during an assessment of the project’s goals and achievements. More than 80% of participants agreed that the course met all expectations; the content was meaningful and challenged their existing views. More than 90% felt that the course meaningfully addressed diversity. Among the successes achieved by the programme is the influence of participants in the student community.
 
Many serve as peer mentors for the Gateway First-Year Welcoming and Orientation Programme, while others serve as mentors in well-being and academic peer advisory programmes. Many have also been elected as members of executive committees of student associations and management committees in residences, while some have availed themselves to run for student governance structures throughout 2011 and 2012.
 
The programme proved to be so successful that it was decided to expand the number of students selected for the programme to 150 this year and first-year students are invited to apply. It is envisaged that 90 students will visit American universities, while 60 will visit institutions in Europe and Asia.
 
Last year the students were hosted by, amongst others, Cornell University, the University of New York, Cleveland State University and the University of Massachusetts.
Yale University, Amherst College and other American universities will join these host universities in 2011, in addition to the European and Asian institutions.
 
Those first-year students who wish to apply can find all the information at www.ufs.ac.za 
 

Media Release
23 March 2011
Issued by: Lacea Loader
Director: Strategic Communication
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: news@ufs.ac.za
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept